Fenofibrate
Sold as Lipanthyl, Tricor, Lipfeno, Fenoglo, Fenotivo
Propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Drag to rotate. Structure from PubChem CID 3339.
Background
Registration
- Applicants
- 3
- Registrations
- 7
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Abbott Laboratories S.A. (Pty) Ltd | Lipanthyl, Tricor | 145 mg, 160 mg, 200 mg | 300494, 410556, 410848, 560113 | S3 | PIPIL |
| Austell Pharmaceuticals (Pty) Ltd | Lipfeno, Fenoglo | Not stated | 560613, 560614.613 | S3 | None |
| Activo Health (Pty) LtdCertificate held by Activo Health (Pty) Ltd. | Fenotivo | 200 mg | 570757 | S3 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lipanthyl 200 MG EACH CAPSULE CONTAINS FENOFIBRATE 200 mg | 200 mg | 30049430/7.5/0494 | Registered | S3 | None |
| Lipanthyl 160 MG EACH TABLET CONTAINS FENOFIBRATE 160,0 mg | 160 mg | 41055641/7.5/0556 | Registered | S3 | None |
| Tricor 160 MG EACH TABLET CONTAINS FENOFIBRATE 160,0 mg | 160 mg | 41084841/7.5/0848 | Registered | S3 | None |
| Lipanthyl 145 MG EACH TABLET CONTAINS FENOFIBRATE 145,0 mg | 145 mgFilm-coated tablets | 56011356/7.5/0113Approved 12 March 2024 | Registered | S3 | PIPIL |
| Lipfeno EACH CAPSULE CONTAINS FENOFIBRATE 200,0 mg | Not listed | 56061356/7.5/0613 | Registered | S3 | None |
| Fenoglo EACH CAPSULE CONTAINS FENOFIBRATE 200,0 mg | Not listed | 560614.61356/7.5/0614.613 | Registered | S3 | None |
| Fenotivo Each Capsule contains: Fenofibrate 200,0 mg | 200 mgCapsule | 57075757/7.5/0757Approved 8 July 2025 | Registered | S3 | PIPIL |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Fenofibrate
S3: Fenofibrate
Consolidated Schedules 06 July 2026, line 3567
Pharmacological class: Serum-cholesterol reducers. (class 7.5)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Lipanthyl 145 MG, Abbott Laboratories S.A. (Pty) Ltd is scheduled S3 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.